Vanguard Group Inc. trimmed its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 1.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,169,665 shares of the medical research company's stock after selling 146,536 shares during the period. Vanguard Group Inc. owned approximately 11.10% of NeoGenomics worth $229,265,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of NEO. First Light Asset Management LLC boosted its stake in NeoGenomics by 29.6% in the fourth quarter. First Light Asset Management LLC now owns 3,926,756 shares of the medical research company's stock valued at $63,535,000 after acquiring an additional 897,843 shares during the last quarter. Redwood Investments LLC bought a new position in NeoGenomics in the fourth quarter valued at approximately $2,399,000. Legato Capital Management LLC bought a new position in NeoGenomics in the fourth quarter valued at approximately $401,000. Norges Bank bought a new position in NeoGenomics in the fourth quarter valued at approximately $14,512,000. Finally, Schroder Investment Management Group boosted its stake in NeoGenomics by 26.7% in the third quarter. Schroder Investment Management Group now owns 2,513,307 shares of the medical research company's stock valued at $30,914,000 after acquiring an additional 529,178 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the stock. Craig Hallum assumed coverage on shares of NeoGenomics in a research report on Wednesday, May 1st. They set a "buy" rating and a $26.00 price target on the stock. Benchmark reissued a "buy" rating and set a $18.00 price target on shares of NeoGenomics in a research report on Wednesday, May 1st. TD Cowen reduced their price target on shares of NeoGenomics from $21.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, May 1st. BTIG Research reduced their price target on shares of NeoGenomics from $23.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday, May 2nd. Finally, Needham & Company LLC reduced their price target on shares of NeoGenomics from $24.00 to $19.00 and set a "buy" rating on the stock in a research report on Tuesday, April 30th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $19.78.
View Our Latest Research Report on NEO
NeoGenomics Stock Down 1.4 %
Shares of NASDAQ:NEO traded down $0.20 during midday trading on Tuesday, reaching $13.73. 583,786 shares of the company were exchanged, compared to its average volume of 853,574. The company has a quick ratio of 7.22, a current ratio of 7.48 and a debt-to-equity ratio of 0.58. NeoGenomics, Inc. has a fifty-two week low of $11.03 and a fifty-two week high of $21.22. The stock has a fifty day simple moving average of $14.08 and a two-hundred day simple moving average of $15.11. The firm has a market cap of $1.75 billion, a PE ratio of -20.80 and a beta of 1.19.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings results on Tuesday, April 30th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). NeoGenomics had a negative net margin of 13.79% and a negative return on equity of 3.54%. The business had revenue of $156.24 million during the quarter, compared to analyst estimates of $149.82 million. As a group, sell-side analysts forecast that NeoGenomics, Inc. will post -0.21 earnings per share for the current year.
NeoGenomics Company Profile
(Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Featured Stories
- Five stocks we like better than NeoGenomics
- Upcoming IPO Stock Lockup Period, Explained
- RXO Shares Surge Following New Acquisition Deal
- How to Capture the Benefits of Dividend Increases
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Canadian Penny Stocks: Can They Make You Rich?
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
→ 1k a day while computer does all work? (From Digital Mavericks Media) (Ad)
Should you invest $1,000 in NeoGenomics right now?
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Beginner's Guide to Pot Stock Investing
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
